Exogenous C-type natriuretic peptide restores normal growth and prevents early growth plate closure in its deficient rats

PLoS One. 2018 Sep 20;13(9):e0204172. doi: 10.1371/journal.pone.0204172. eCollection 2018.

Abstract

Signaling by C-type natriuretic peptide (CNP) and its receptor, natriuretic peptide receptor-B, is a pivotal stimulator of endochondral bone growth. We recently developed CNP knockout (KO) rats that exhibit impaired skeletal growth with early growth plate closure. In the current study, we further characterized the phenotype and growth plate morphology in CNP-KO rats, and the effects of exogenous CNP in rats. We used CNP-53, an endogenous form of CNP consisting of 53 amino acids, and administered it for four weeks by continuous subcutaneous infusion at 0.15 or 0.5 mg/kg/day to four-week old CNP-KO and littermate wild type (WT) rats. We demonstrated that CNP-KO rats were useful as a reproducible animal model for skeletal dysplasia, due to their impairment in endochondral bone growth. There was no significant difference in plasma bone-turnover markers between the CNP-KO and WT rats. At eight weeks of age, growth plate closure was observed in the distal end of the tibia and the calcaneus of CNP-KO rats. Continuous subcutaneous infusion of CNP-53 significantly, and in a dose-dependent manner, stimulated skeletal growth in CNP-KO and WT rats, with CNP-KO rats being more sensitive to the treatment. CNP-53 also normalized the length of long bones and the growth plate thickness, and prevented growth plate closure in the CNP-KO rats. Using organ culture experiment of fetal rat tibia, gene set enrichment analysis indicated that CNP might have a negative influence on mitogen activated protein kinase signaling cascades in chondrocyte. Our results indicated that CNP-KO rats might be a valuable animal model for investigating growth plate physiology and the mechanism of growth plate closure, and that CNP-53, or its analog, may have the potential to promote growth and to prevent early growth plate closure in the short stature.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / blood
  • Body Weight / drug effects
  • Bone Remodeling
  • Female
  • Gene Knockout Techniques
  • Growth Plate / drug effects
  • Growth Plate / growth & development*
  • Growth Plate / pathology
  • Humans
  • Hypertrophy
  • Ligands
  • MAP Kinase Signaling System / drug effects
  • Male
  • Natriuretic Peptide, C-Type / deficiency*
  • Natriuretic Peptide, C-Type / genetics
  • Natriuretic Peptide, C-Type / metabolism
  • Natriuretic Peptide, C-Type / pharmacology*
  • Phenotype
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Rats
  • Receptors, Atrial Natriuretic Factor / genetics
  • Receptors, Atrial Natriuretic Factor / metabolism
  • Tibia / drug effects
  • Tibia / pathology

Substances

  • Biomarkers
  • Ligands
  • RNA, Messenger
  • Natriuretic Peptide, C-Type
  • Receptors, Atrial Natriuretic Factor

Grants and funding

This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (21591176 and JP 17K09881), and the Uehara Memorial Foundation. Asubio Pharma Co., Ltd. provided support in the form of salaries for authors [MF, NM, KY, TY, TJ, RN, TH, HS, SY and KE], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.